- Conditions
- Alzheimer Disease
- Interventions
- Transcranial Alternating Current Stimulation (tACS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 618
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alzheimer Disease
- Interventions
- cycloastragenol, placebo (for cycloastragenol)
- Dietary Supplement
- Lead sponsor
- Chippewa Valley Eye Clinic
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Eau Claire, Wisconsin
- Conditions
- Alzheimer's Disease
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2026
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more
- Conditions
- Parkinson Disease, Neurological Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Pemetrexed
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cardiac Amyloidosis
- Interventions
- EchoNet-LVH screening for cardiac amyloidosis
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
- Interventions
- Isatuximab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 345
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more
- Conditions
- Relapsed/Refractory Systemic Light Chain Amyloidosis
- Interventions
- Linvoseltamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 8
- States / cities
- Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
- Interventions
- LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 10
- States / cities
- Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Transcranial Alternating Current Stimulation (tACS), Sham Transcranial Alternating Current Stimulation
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Psoriasis, Plaque-type Psoriasis
- Interventions
- secukinumab, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
- Conditions
- Alzheimer Disease, Alzheimer Dementia
- Interventions
- Blood collection, PiB PET/MRI, and cognitive testing
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,122 participants
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
- Interventions
- Patisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more
- Conditions
- Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
- Interventions
- 18F-AV-1451
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
- Interventions
- Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- Up to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, dexamethasone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transthyretin Amyloidosis
- Interventions
- Cardiac MRI
- Diagnostic Test
- Lead sponsor
- The Christ Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- Birtamimab, Placebo, Standard of Care Chemotherapy
- Drug · Other
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 22
- States / cities
- North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more
- Conditions
- Immunoglobulin Light Chain (AL) Amyloidosis
- Interventions
- ABBV-383 (Etentamig)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- Interventions
- NNC6019-0001, Placebo (NNC6019-0001)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Stanford, California + 5 more
- Conditions
- Amyloidosis; Systemic
- Interventions
- AT02
- Drug
- Lead sponsor
- Attralus, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Cleveland, Ohio • Portland, Oregon + 1 more
- Conditions
- Plaque, Gingivitis
- Interventions
- 2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W, 10 mg KSL-W, 20 mg KSL-W, 30 mg KSL-W, 50 mg KSL-W, 75 mg KSL-W, 100 mg KSL-W, Placebo
- Drug · Other
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Bioavailability, Gut Microbiome, Safety
- Interventions
- Low curcumin group, High curcumin group
- Drug
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 40 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Lubbock, Texas